Osteoporosis & Fragility Fractures in Older Adults: DEXA Screening, Anabolic Therapy & Fall Prevention

1. The Silent Epidemic of Progressive Bone Mineral Loss

Osteoporosis is a systemic metabolic skeletal disease characterized by compromised bone mineral density (BMD) and progressive microarchitectural deterioration of cancellous and cortical bone tissue. Termed the "silent epidemic," osteoporosis advances without causing overt pain or symptoms until an elderly individual suffers a catastrophic low-energy fragility fracture from a simple standing-height fall or minor torsional twist. In India, an estimated 50 million individuals live with osteoporosis or severe osteopenia, with postmenopausal women and older males bearing an extraordinarily high burden of morbidity and mortality related to hip and vertebral compression fractures.

2. Understanding Dual-Energy X-ray Absorptiometry (DEXA) T-Scores

The World Health Organization (WHO) gold standard for diagnosing osteoporosis is central DEXA scanning of the lumbar spine (L1-L4) and proximal femur (femoral neck and total hip):

• Normal Bone Density: T-score between +1.0 and -1.0 Standard Deviations (SD) relative to young adult peak bone mass.
• Osteopenia (Low Bone Mass): T-score between -1.0 and -2.5 SD, representing an early intervention window.
• Established Osteoporosis: T-score at or below -2.5 SD at any measured skeletal site.
• Severe / Established Osteoporosis: T-score <= -2.5 SD accompanied by one or more documented low-trauma fragility fractures.
• FRAX Tool Assessment: The WHO Fracture Risk Assessment Tool calculates the 10-year probability of major osteoporotic fracture and hip fracture, guiding pharmacological treatment thresholds even in osteopenic ranges.

"A hip or vertebral fragility fracture in an elderly patient is an orthopaedic emergency. Prompt surgical stabilization within 24 to 48 hours followed by aggressive anabolic bone therapy cuts 1-year mortality by half and restores functional independence." — Dr. Deepak Garg

3. Pharmacological Arsenal: Antiresorptive vs. Bone-Building Anabolic Agents

Modern osteoporosis pharmacotherapy combines two distinct classes of medications based on fracture risk stratification:

1. Anabolic Bone-Forming Therapy (Teriparatide / Abaloparatide / Romosozumab): Recombinant human parathyroid hormone analogs that stimulate osteoblastic bone matrix synthesis and rapidly rebuild trabecular micro-architecture. Indicated for very high fracture risk (T-score <= -3.0 or multiple fractures).
2. Bisphosphonates (Zoledronic Acid 5 mg IV Annual Infusion / Oral Alendronate): Potent inhibitors of osteoclastic bone resorption, providing long-term skeletal retention and reducing vertebral/hip fracture rates by up to 70%.
3. RANK-Ligand Monoclonal Inhibitors (Denosumab 60 mg SC Every 6 Months): Highly effective in postmenopausal osteoporosis and patients with chronic renal insufficiency where bisphosphonates are contraindicated.
4. Baseline Nutritional Optimization: Mandatory daily elemental calcium (1,000–1,200 mg) and maintenance Vitamin D3 (2,000 IU daily or 60,000 IU monthly) to maintain serum 25-OH-D levels >30-50 ng/mL.

4. Surgical Management of Acute Geriatric Fragility Fractures

When elderly bones fail, immediate surgical intervention prevents prolonged bed-rest complications (pneumonia, deep vein thrombosis, decubitus ulcers):

• Intertrochanteric & Subtrochanteric Femur Fractures: Stabilized with Cephalomedullary Proximal Femoral Nails (PFNA) utilizing helical blades for superior purchase in osteoporotic bone.
• Femoral Neck Fractures: Treated with Bipolar Hemiarthroplasty or Total Hip Arthroplasty (THA) using cementation to allow immediate full weight-bearing on Day-1.
• Vertebral Compression Fractures: Managed with Minimally Invasive Balloon Kyphoplasty / Vertebroplasty, delivering bone cement into collapsed vertebral bodies under fluoroscopic guidance to provide instant pain relief and restore spinal height.

5. Comprehensive Home Safety & Fall-Prevention Protocol

Over 90% of geriatric hip fractures occur following indoor falls. Modifying environmental hazards and conducting medication reviews (reducing sedatives, psychotropics, and antihypertensives causing orthostatic hypotension), installing non-slip bathroom grab rails, ensuring high-lumen night lighting, and prescribing gait and balance physical therapy dramatically lower annual fall incidents.

6. Scientific References & Clinical Guidelines

1. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis. Endocr Pract, 2020; 26(Suppl 1): 1-46.

2. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int, 2014; 25(10): 2359-2381.

3. Indian Society for Bone and Mineral Research (ISBMR) Clinical Practice Guidelines on Postmenopausal Osteoporosis, 2023.